A Phase II Trial of Rituximab + Oblimersen Sodium (GenasenseTM, G3139, NSC 683428, IND 58842) in Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2013
At a glance
- Drugs Oblimersen (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 04 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Nov 2007 Status changed from in progress to completed.
- 30 Jul 2007 Status changed from recruiting to in progress.